Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

840 > HIV > Flashcards

HIV Flashcards

1
Q

Life Cycle

A
  1. Viral Entry
  2. Reverse transcriptase creates viral DNA
  3. Viral integrase integrates viral DNA into nucleus and genome
  4. Transcription/translation occurs forming viral
    proteins
  5. Proteins are then cleaved and used in new HIV organism assembly
  6. HIV organisms mature an bud off host cell to infect other cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HIV Etiology

A
  • Retrovirus (RNA => DNA via reverse transcriptase)
  • Infects the immune system, mainly CD4 receptors of T-cells
  • Can also infect monocytes, macrophages, and dock CD4- cells to infect them
  • HIV-1 is majority of US cases
  • HIV-2 is less virulent and mainly seen in Africa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HIV Diagnostic Tests

A
  • HIV Antibodies: most common test for established infection
  • HIV-1 RNA: used for actute HIV and indeterminate WB
  • HIV p24 Antigen: 4th generation EIA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Routine Screening for HIV Infection

A
  1. All patients aged 13-64 in all health care settings
  2. Patients seeking treatment for STDs
  3. Patients initiating tuberculosis treatment
  4. Pregnant patient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HIV Stages

A
  • Stage 0: Early HIV infection
  • Stage 1: CD4>500, >=26%, no AIDS-defining condition
  • Stage 2: CD4 200-499, 14-26%, no AIDS-defining condition
  • Stage 3: CD4 <200, <14%, no documentation of AIDS-defining condition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HIV Transmission

A
  • Found in blood, urine, semen, vaginal secretions, uterine cervix, breast milk, CSF, alveolar fluid
  • Unprotected sex with infected partner
  • Sharing needles
  • Infection from blood products
  • Transmission from mother to fetus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HIV Goals of Treatment

A
  • Reduce HIV-related morbidity (prolong duration and quality of survival)
  • Restore and/or preserve immunologic function
  • Maximally and durably suppress HIV viral load
  • Prevent HIV transmission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Adherence

A
  • Major determinant of degree and duration of viral suppression
  • Poor adherence associated with virologic failure
  • Optimal suppression requires excellent adherence
  • Suboptimal adherence is common
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Predictors of Inadequate Adherence

A
  • Regimen complexity and pill burden
  • Poor clinician-patient relationship
  • Active drug use or alcoholism
  • Unstable housing
  • Mental illness (especially untreated depression)
  • Lack of patient education
  • Medication AE (fear of them)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When to Start ART

A
  • Art is recommended for treatment and for prevention
  • A1 recommendation
  • Recommended regardless of CD4 count
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ART Initiation Considerations

A
  • ART should be started as soon as possible, could be deferred due to clinical/psychological factors
  • Indefinite treatment is required, doesn’t cure HIV
  • Address strategies to optimize adherence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Considerations for HAART

A
  • ARV Resistance: prior regimens and resistance tests
  • Comorbid conditions: renal disease, HBV, osteoporosis, pregnancy
  • Drug absorption: acidic stomach, chelators, food requirement
  • Drug interactions: need current medication list
  • Insurance/formulary
  • Patient preference: pill count, food requirements, dosing frequency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Baseline Data

A
  • Complete metabolic panel
  • CBC with differential
  • Urinalysis
  • Blood glucose
  • Lipid panel
  • Pregnancy test
  • Current medication list
  • Comorbidities
  • CD4 Count (All)
  • HIV Viral Load (All)
  • Serologies for Hep A/B/C (All)
  • Genotype-test for resistance (All)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CD4 Count Importance

A
  • Used to stage disease
  • Immune function assessment
  • Assess if OI prophylaxis is needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HIV Viral Load Importance

A
  • May help provider decide on regimen

- Baseline value which is tracked to gauge treatment efficacy and adherence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drug Resistance Testing

A

Before ART Initiation:

  • Transmitted resistance occurs in 10-17% of infected patients
  • Absence of therapy may decline over time for detection but still cause treatment failure
  • Identification of resistance mutations can optimize treatment outcomes
  • Resistance testing is recommended for all at entry to care (include INSTI if suspected)
  • Recommended for all pregnant women

Virological Failure:

  • Perform while patient is taking ART, or =<4 weeks after D/C therapy
  • Interpret in combination with history of ARV exposure and adherence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

HLA-B*5701 Screening

A
  • Recommended before starting ABC, to reduce risk of hypersensitivity reaction
  • Positive patients shouldn’t receive ABC
  • Positive status should be recorded as ABC allergy
  • If testing isn’t available, ABC may be initiated but only after counseling and with appropriate monitoring for HSR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Coreceptor Tropism Assay

A
  • Should be performed when a CCR5 antagonist is being considered
  • Phenotype assays have been used; genotype test now available but has been studied less thoroughly
  • Consider in patients with virological failure on CCR5 antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Initial ART Regimens: DHHS Categories

A
  • Recommended in Most people: easy to use, durable efficacy, favorable tox/tolerability profiles
  • Recommended in Certain Clinical Situations: Effective but have potential disadvantages, limitations in populations, less supporting data, may be optimal for certain patients
  • Other: reduced virological activity, greater toxicities, higher pill burden, other limiting factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Initial Regimen (HAART)

A

NRTI Background + Integrase Inhibitor

21
Q

Preferred NRTI Backbone Choices

A
  • Tenofovir + Emtricitabine (Truvada)
  • Tenofovir alafenamide (TAF) + emtricitabrine (Descovy)
  • Abacavir + Lamivudine only as part of Triumeq (dolutegravir too): only if HLA-b*5701 is absent
22
Q

Initial Regimen Options

A
  • Highly vary
  • Can be INSTI, NNRTI, PI, or INSTI based
  • Can focus on single pill regimens
  • Differ by guidelines
  • NRTI-sparing (when it can’t be used)
23
Q

Special Consideration + Initial Regimens

A
  • TDF not recommended in those with kidney or bone disease
  • 2-drug regimens are only recommended when abacavir, TAF, or TDF can’t be taken
  • Pregnant individuals should initiate ART ASAP
24
Q

Lab Monitoring: Viral Load

A
  • 2-4 weeks after starting ART and no later than 8, repeat at 4- and 8- weeks until undetectable
  • Goal to be undetectable within 8-24 weeks
  • Every 6 mo if undetectable after 2 years
  • If regimen is modified, repeat viral load within 4-8 weeks after change
25
Q

Lab Monitoring: CD4

A
  • Adequate response to therapy: 50-150 cell increase during 1st year of ART
  • 3 mo after initiation of ART is preferred for treatment
  • If stable CD4 (300-500) after 2 years, measure every year
  • If CD4 > 500 after 2 years, monitoring is optional
26
Q

Bictegravir Advantages

A
  • Once daily and coformulated with TAF/FTC
  • Non-inferior to DTG
  • Low-risk resistance
  • With or without food
  • Few drug interactions
27
Q

Bictegravir Disadvantages

A
  • Cannot be used with rifampin
  • Limited data (new)
  • Raised SCr
  • Limited pregnancy data
  • Concern for neural tubal defects
28
Q

Dolutegravir Advantages

A
  • Superior to DRV and EFV
  • Once-daily
  • Available as single agent
  • High resistance barrier
  • Few drug interactions
  • With or without food
  • Superior to RTG in experienced patients
29
Q

Dolutegravir Disadvantages

A
  • Raises SCr
  • Higher rates of insomnia/headache
  • With ABC/3TC = largest tablet
  • Concern for neural tubal defects
30
Q

Elvitegravir Advantages

A
  • Once daily

- Co-formulated

31
Q

Elvitegravir Disadvantages

A
  • Requires PK booster
  • Low resistance barrier
  • Drug interactions
  • Raises SCr
  • Food
  • Avoid in pregnancy
  • Concern for neural tubal defects
32
Q

Raltegravir Advantages

A
  • Superior to ritonavir-boosted DRV, ATV
  • Longest safety record
  • Fewest DDI
  • With or without food
33
Q

Raltegravir Disadvantages

A
  • Not co-formulated
  • Lower barrier to resistance than DTG, BTG
  • Higher pill burden (own pill, not co-formulated)
  • Concern for neural tubal defects
34
Q

Patient Characteristics Considerations + Initiating ART

A
  • HIV RNA; CD4 count
  • HIV resistance test results
  • HLA-B*5701 status
  • Patient preferences
  • Anticipated adherence
35
Q

Comorbidities Considerations + Initiating ART

A
  • CV disease, hyperlipidemia, renal disease, osteoporosis, psychiatric illness
  • Pregnancy or pregnancy potential
  • Coinfections: HCV, HBV, TB
36
Q

Regimen Characteristics Considerations + Initiating ART

A
  • Genetic barrier to resistance
  • Potential adverse effects
  • Drug interactions with other medications
  • Convenience (pill #/frequency)
  • Cost
37
Q

CD4 < 200: Drugs to Avoid

A
  • Rilpivirine

- Darunavir/r + Raltegravir

38
Q

HIV RNA > 100,000: Drugs to Avoid

A
  • Rilpivirine based ART

- ABC/3TC + EFV or ATV/r

39
Q

HLAB*5701 Positive: Drugs to Avoid

A

ABC

40
Q

HIV Drugs + Food

A
  • Have to boost? Take with food
  • Rilpivirine also requires food
  • EFV requires an empty stomach (bedtime)
  • Raltegravir and Dolutegravir can be taken without regards to food
41
Q

eGFR < 60 + HIV Drugs

A
  • Avoid TDF
  • Use ABC or TAF (latter used in eGFR >= 30)

-LPV + 3TC or DRV/r + RAL can be used is TAF or ABC can’t be used (unlikely scenario)

42
Q

Osteopororsis + HIV Drugs

A
  • Avoid TDF

- Use ABC or TAF

43
Q

Psychiatric Illness + HIV Drugs

A
  • Consider avoiding EFV and Rilpivirine

- Exacerbates symptoms and can be associated with suicidality

44
Q

HIV-associated Dementia + HIV Drugs

A
  • Avoid EFV

- Favor Darunavir or DTG-based regimens

45
Q

Methadone + HIV Drugs

A
  • Avoid EFV-based regimens if receiving methadone

- May have to increase methadone dose if EFV must be used

46
Q

Cardiac Risk: Drugs to Avoid

A
  • ABC
  • Lopinavir/r
  • EFV or Rilpivirine regimens especially with other torsades risk drugs
47
Q

Hyperlipidemia + HIV Drugs

A

Avoid

  • PI based regimens (regardless of booster)
  • EFV
  • Elvitegravir/c

-TDF beneficial for cholesterol

48
Q

HBV + HIV Drugs

A

Use TDF or TAF with Emtricitabine (FTC) or Lamivudine (3TC) whenever possible

49
Q

TB + HIV Drugs

A
  • TAF not recommended to use with rifamycins (decreases its exposure)
  • In a PI-based regimen, use rifabutin instead of rifampin

If Rifamycins used:

  • EFV (no adjustment)
  • Raltegravir (800 mg BID)
  • DTG (50 mg BID if no significant INSTI mutations)

840 (17 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions